• Something wrong with this record ?

Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects

P. Šponer, T. Kučera, J. Brtková, K. Urban, Z. Kočí, P. Měřička, A. Bezrouk, Š. Konrádová, A. Filipová, S. Filip,

. 2018 ; 27 (10) : 1459-1468. [pub] 20180911

Language English Country United States

Document type Clinical Trial, Phase II, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19045252

This prospective study sought to evaluate the healing quality of implanted ultraporous β-tricalcium phosphate sown with expanded autologous mesenchymal stromal cells (MSCs) into femoral defects during revision hip arthroplasty. A total of 37 osseous defects in 37 patients were treated and evaluated concerning bone regeneration. Nineteen subjects received β-tricalcium phosphate graft material serving as a carrier of expanded autologous MSCs (the trial group A), nine subjects received β-tricalcium phosphate graft material only (the study group B) and nine subjects received cancellous allografts only (the control group C). Clinical and radiographic evaluations were scheduled at 6 weeks, 3, 6, and 12 months post-operatively, and performed at the most recent visit as well. All observed complications were recorded during follow-up to assess the use of an ultraporous β-tricalcium phosphate synthetic graft material combined with expanded MSCs in bone defect repair. The resulting data from participants with accomplished follow-up were processed and statistically evaluated with a Freeman-Halton modification of the Fischer's exact test, a P < 0.05 value was considered to be significant. Whereas no significant difference was observed between the trial group A with β-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs and control group C with cancellous impaction allografting in terms of the bone defect healing, significant differences were documented between the study group B with β-tricalcium phosphate graft material only and control group C. Regarding adverse effects, six serious events were recorded during the clinical trial with no causal relationship to the cell product. β-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs appears safe and promotes the healing of bone defects in a jeopardized and/or impaired microenvironment. This clinical trial was registered at the EU Clinical Trials Register before patient recruitment (Registration number: EudraCT number 2012-005599-33; Date of registration: 2013-02-04).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045252
003      
CZ-PrNML
005      
20200113105528.0
007      
ta
008      
200109s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/0963689718794918 $2 doi
035    __
$a (PubMed)30203687
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Šponer, Pavel $u 1 Department of Orthopaedic Surgery, University Hospital, Hradec Králové, Czech Republic.
245    10
$a Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects / $c P. Šponer, T. Kučera, J. Brtková, K. Urban, Z. Kočí, P. Měřička, A. Bezrouk, Š. Konrádová, A. Filipová, S. Filip,
520    9_
$a This prospective study sought to evaluate the healing quality of implanted ultraporous β-tricalcium phosphate sown with expanded autologous mesenchymal stromal cells (MSCs) into femoral defects during revision hip arthroplasty. A total of 37 osseous defects in 37 patients were treated and evaluated concerning bone regeneration. Nineteen subjects received β-tricalcium phosphate graft material serving as a carrier of expanded autologous MSCs (the trial group A), nine subjects received β-tricalcium phosphate graft material only (the study group B) and nine subjects received cancellous allografts only (the control group C). Clinical and radiographic evaluations were scheduled at 6 weeks, 3, 6, and 12 months post-operatively, and performed at the most recent visit as well. All observed complications were recorded during follow-up to assess the use of an ultraporous β-tricalcium phosphate synthetic graft material combined with expanded MSCs in bone defect repair. The resulting data from participants with accomplished follow-up were processed and statistically evaluated with a Freeman-Halton modification of the Fischer's exact test, a P < 0.05 value was considered to be significant. Whereas no significant difference was observed between the trial group A with β-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs and control group C with cancellous impaction allografting in terms of the bone defect healing, significant differences were documented between the study group B with β-tricalcium phosphate graft material only and control group C. Regarding adverse effects, six serious events were recorded during the clinical trial with no causal relationship to the cell product. β-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs appears safe and promotes the healing of bone defects in a jeopardized and/or impaired microenvironment. This clinical trial was registered at the EU Clinical Trials Register before patient recruitment (Registration number: EudraCT number 2012-005599-33; Date of registration: 2013-02-04).
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    12
$a regenerace kostí $7 D001861
650    _2
$a kostní náhrady $x chemie $x terapeutické užití $7 D018786
650    _2
$a fosforečnany vápenaté $x chemie $x terapeutické užití $7 D002130
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a femur $x cytologie $x zranění $x fyziologie $x chirurgie $7 D005269
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a transplantace mezenchymálních kmenových buněk $x metody $7 D045164
650    _2
$a mezenchymální kmenové buňky $x cytologie $7 D059630
650    _2
$a lidé středního věku $7 D008875
650    _2
$a tkáňové podpůrné struktury $x chemie $7 D054457
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kučera, Tomáš $u 1 Department of Orthopaedic Surgery, University Hospital, Hradec Králové, Czech Republic.
700    1_
$a Brtková, Jindra $u 2 Department of Radiology, University Hospital, Hradec Králové, Czech Republic.
700    1_
$a Urban, Karel $u 1 Department of Orthopaedic Surgery, University Hospital, Hradec Králové, Czech Republic.
700    1_
$a Kočí, Zuzana $u 3 Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Měřička, Pavel $u 4 Tissue Bank, University Hospital, Hradec Králové, Czech Republic.
700    1_
$a Bezrouk, Aleš $u 5 Department of Medical Biophysics, Charles University, Faculty of Medicine Hradec Králové, Czech Republic.
700    1_
$a Konrádová, Šimona $u 3 Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Filipová, Alžběta $u 6 Department of Radiobiology, Faculty of Military Health Sciences in Hradec Králové, University of Defence in Brno, Czech Republic.
700    1_
$a Filip, Stanislav $u 7 Department of Oncology and Radiotherapy, Charles University, Faculty of Medicine Hradec Králové, Czech Republic.
773    0_
$w MED00001075 $t Cell transplantation $x 1555-3892 $g Roč. 27, č. 10 (2018), s. 1459-1468
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30203687 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113105900 $b ABA008
999    __
$a ok $b bmc $g 1483521 $s 1083925
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 27 $c 10 $d 1459-1468 $e 20180911 $i 1555-3892 $m Cell transplantation $n Cell Transplant $x MED00001075
LZP    __
$a Pubmed-20200109
Back

Find record

Citation metrics

Archiving options